We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » IOM Study Could Harm Industry's Bottom Line, Spur Legislative Changes
IOM Study Could Harm Industry's Bottom Line, Spur Legislative Changes
September 29, 2006
The Institute of Medicine (IOM) report on the FDA’s drug safety practices could do long-term damage to industry revenue and will likely spur legislation in the next Congress, sources say.